Tenecteplase for the Treatment of Pediatric Arterial Ischemic Stroke: A Safety Surveillance Report.

IF 7.7 1区医学 Q1 CLINICAL NEUROLOGY

Neurology Pub Date : 2025-02-11 Epub Date: 2025-01-13 DOI:10.1212/WNL.0000000000210310

Lisa R Sun, Sarah Lee, Jacqueline Lee-Eng, Megan Barry, Maria M Galardi, Dana Harrar, Sahar M Hassanein, Michael J Rivkin, Marcela Torres, Jenny L Wilson, Catherine Amlie-Lefond, Kristin Guilliams

{"title":"Tenecteplase for the Treatment of Pediatric Arterial Ischemic Stroke: A Safety Surveillance Report.","authors":"Lisa R Sun, Sarah Lee, Jacqueline Lee-Eng, Megan Barry, Maria M Galardi, Dana Harrar, Sahar M Hassanein, Michael J Rivkin, Marcela Torres, Jenny L Wilson, Catherine Amlie-Lefond, Kristin Guilliams","doi":"10.1212/WNL.0000000000210310","DOIUrl":null,"url":null,"abstract":"Objectives: Intravenous tenecteplase (TNK) is increasingly used to treat adult patients with acute arterial ischemic stroke, but the risk profile of TNK in childhood stroke is unknown. This study aims to prospectively gather safety data regarding TNK administration in children.Methods: Since December 2023, a monthly email survey was sent to participants recruited from the International Pediatric Stroke Study and Pediatric Neurocritical Care Research Group querying recent experience with TNK in childhood stroke. Limited demographic, safety, and outcome data were collected in a secure REDCap database. Detailed clinical data were not collected.Results: Eleven children were reported to have received TNK between February 2023 and January 2024. Ten were adolescents (13-17 years old), and 1 was between 5 and 12 years old. TNK was given at an outside facility before transfer to the reporting facility in 7 cases. Final diagnosis was stroke in 8 cases and stroke mimic in 3 cases. No major safety concerns or TNK-related intracranial hemorrhages on follow-up imaging were reported.Discussion: Our initial data suggest that TNK may be safe in childhood arterial ischemic stroke. Strategically designed prospective studies are needed to further define safety, optimal dosage, and efficacy of TNK in acute pediatric stroke.","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"104 3","pages":"e210310"},"PeriodicalIF":7.7000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/WNL.0000000000210310","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Intravenous tenecteplase (TNK) is increasingly used to treat adult patients with acute arterial ischemic stroke, but the risk profile of TNK in childhood stroke is unknown. This study aims to prospectively gather safety data regarding TNK administration in children.

Methods: Since December 2023, a monthly email survey was sent to participants recruited from the International Pediatric Stroke Study and Pediatric Neurocritical Care Research Group querying recent experience with TNK in childhood stroke. Limited demographic, safety, and outcome data were collected in a secure REDCap database. Detailed clinical data were not collected.

Results: Eleven children were reported to have received TNK between February 2023 and January 2024. Ten were adolescents (13-17 years old), and 1 was between 5 and 12 years old. TNK was given at an outside facility before transfer to the reporting facility in 7 cases. Final diagnosis was stroke in 8 cases and stroke mimic in 3 cases. No major safety concerns or TNK-related intracranial hemorrhages on follow-up imaging were reported.

Discussion: Our initial data suggest that TNK may be safe in childhood arterial ischemic stroke. Strategically designed prospective studies are needed to further define safety, optimal dosage, and efficacy of TNK in acute pediatric stroke.

查看原文本刊更多论文

替奈普酶治疗小儿动脉缺血性脑卒中的安全性监测报告

目的：静脉注射替奈普酶（TNK）越来越多地用于治疗急性动脉缺血性卒中成人患者，但TNK在儿童卒中中的风险情况尚不清楚。本研究旨在前瞻性地收集儿童使用TNK的安全性数据。方法：自2023年12月起，每月向国际儿科卒中研究和儿科神经危重症护理研究小组招募的参与者发送电子邮件调查，询问最近在儿童卒中中使用TNK的经验。有限的人口统计学、安全性和结局数据收集在一个安全的REDCap数据库中。没有收集详细的临床资料。结果：11名儿童在2023年2月至2024年1月期间接受了TNK治疗。10例为青少年（13-17岁），1例为5 - 12岁。在转移到报告机构之前，有7例在外部设施给予秋明。最终诊断为脑卒中8例，脑卒中模拟3例。随访影像学无重大安全问题或秋明相关颅内出血报道。讨论：我们的初步数据表明，TNK在儿童动脉缺血性卒中中可能是安全的。需要战略性设计的前瞻性研究来进一步确定TNK在急性小儿卒中中的安全性、最佳剂量和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology 医学-临床神经学

CiteScore

12.20

自引率

4.00%

发文量

1973

审稿时长

2-3 weeks

期刊介绍： Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology. As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content. Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.